Login with ORCID

association

Full identifier: http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association

Assigned to 1 class:

Minted in Nanopublication

 RACNyW-Z21 comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RACNyW-Z21... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal)
(xsd:dateTime)
.
This is the identifier for this whole nanopublication. http://purl.org/np/RACNyW-Z21... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI...
.
This is the identifier for this whole nanopublication. http://purl.org/np/RACNyW-Z21... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW...
.
This is the identifier for this whole nanopublication. http://purl.org/np/RACNyW-Z21... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC...
.

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
azilect rasagiline tablets is indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease as initial monotherapy and as adjunct therapy to levodopa the effectiveness of azilect was demonstrated in patients with early parkinson s disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinson s disease who were treated with levodopa azilect is indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease as initial monotherapy and as adjunct therapy to levodopa 1
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T11:08:24.095Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)